PTC THERAPEUTICS, INC. PTCT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
1.56
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.7B | $682.6M | — | $702.3M | -$205.3M |
| 2024 | $806.8M | -$363.3M | — | -$114.2M | -$1.1B |
| 2023 | $937.8M | -$626.6M | — | -$186.9M | -$818.6M |
| 2022 | $698.8M | -$559.0M | — | -$388.7M | -$347.1M |
| 2021 | $538.6M | -$523.9M | — | -$279.5M | $1.4M |
| 2020 | $380.8M | -$438.2M | — | -$211.9M | $482.0M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.56 (grey)
- Working capital / assets 0.45
- Retained earnings / assets -1.023
- EBIT / assets 0.299
- Equity / liabilities -0.066
Source: SEC EDGAR filings · CIK 0001070081 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.